Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Action Observation Therapy in Children With Spastic Diplegia

NCT07651111 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-06-20
Last updated
2026-06-16

Condition(s) studied

Spastic Diplegia

Investigational drug(s) / intervention(s)

A selected physical therapy programLive action observation training (AOT)Video action observation training (AOT)

A selected physical therapy program: Participants will receive a conventional physical therapy program, 3 sessions per week for 3 months. The program will include approximation exercises, balance training, functional activities (sit-to-stand, squatting, stair climbing), gait training with obstacles, walking exercises on different surfaces, and stretching exercises for the upper and lower limbs. The intervention aims to improve balance, mobility, coordination, and functional performance.

Live action observation training (AOT): Participants will receive live AOT for 30 minutes, 3 times per week, for 3 months. Each task will involve 3 minutes of observing the therapist performing the activity, followed by 3 minutes of verbal guidance and 3 minutes of task execution by the child. A 1-minute rest period will be provided between tasks.

Video action observation training (AOT): Participants will receive video-based AOT for 30 minutes, 3 times per week, for 3 months. They will observe task demonstrations presented on a computer screen from multiple viewing angles, followed by guided practice and task performance, similar to the live AOT protocol.

Study summary

The aim of this study is to compare the effect of live versus video action observation training (AOT) on balance and gait in children with spastic diplegia.

Eligibility

Sex
ALL
Min age
4 Years
Max age
7 Years
Healthy volunteers
No
Inclusion Criteria: * Children of diplegia who walk by a crouch gait. * The age of the selected children will range from 4 to 7 years old. * Degree of spasticity will range from 1 to 1+, according to modified Ashworth scale (MAS). * They will be selected as Level II according to Gross motor function classification system (GMFCS). * They will be able to understand the tasks and researchers' instructions. * Their heights are not less than 1 meter to be able to see the screen of the Biodex balance system. Exclusion Criteria: * Visual or auditory impairments. * Vestibular impairments. * Fixed deformities of the upper, lower limbs, and the spine. * Botulinum toxin (Botox) injection for the last six months. * Orthopedic surgeries in the last six months.

Primary outcome measure(s)

  • Overall Stability Index (OSI) — 3 months
    It will be assessed using the Biodex Balance System. Participants will stand on a dynamic platform at stability level 5 for three 30-second trials. The Overall Stability Index (OSI) will be recorded as a measure of postural stability in all directions. Lower OSI values indicate better balance control and greater postural stability.
  • Anteroposterior Stability Index (APSI) — 3 months
    It will be measured using the Biodex Balance System during dynamic balance testing. APSI reflects the participant's ability to maintain balance in the forward and backward directions. Lower APSI scores indicate improved anteroposterior postural control.
  • Mediolateral Stability Index (MLSI) — 3 months
    It will be assessed using the Biodex Balance System. MLSI evaluates the participant's ability to control balance in the side-to-side direction during dynamic standing. Lower MLSI values indicate better mediolateral stability and balance performance.

Trial sites (1)

FacilityCityRegionStatus
Outpatient clinic of the Faculty of physical therapy, Cairo University Giza Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07651111 on ClinicalTrials.gov ↗ ← All trials in Egypt